Chris Garabedian

Biotech Hangout welcomes biotech analysts Josh Schimmer, Tim Opler, Chris Garabedian, Dawn Bell, and guest host Eric Schmidt. They cover topics such as the JPM year in review, XBI performance, Abbvie's acquisition of Cerevel, big GLP-1 deal from Roche and Carmot, AstraZeneca/IRA case, three big investors days from J&J, Sanofi and Neurocrine Biosciences, CVS's drug coverage update, and Eyepoint Pharmaceutical's wet AMD data.

Join Chris Garabedian, Chairman & CEO of Xontogeny, as he discusses strategic design choices in early drug development in biotech, optimizing biotech investments for success, and the future of precision medicine in the industry. Learn about his transition from marketing to biopharmaceuticals, the power of analytical thinking, and the importance of mentorship in driving innovation.